We used the Cardiovascular Disease Policy Model to estimate the cost-effectiveness of the ACC/AHA guideline relative to current use, Adult Treatment Panel III guidelines, and universal statin use in all men 45 to 74 years of age and women 55 to 74 years of age over a 10-year horizon from 2016 to 2025. Sensitivity analyses varied costs, risks, and benefits. Main outcomes were incremental cost-effectiveness ratios and numbers needed to treat for 10 years per quality-adjusted life-year gained.
C
oronary heart disease (CHD) is the leading cause of death worldwide. 1 Inhibitors of HMG-CoA reductase, or statins, prevent CHD events and mortality in individuals with known cardiovascular disease or risk equivalents 2 and prevent CHD in asymptomatic low-risk individuals. 3 Given this potential benefit, many have suggested wide indications for their use and availability without a prescription. This view has been reinforced by the decreasing cost of statins, 4 evidence that toxicities may be less than previously believed, 5, 6 and studies supporting benefits in lower-risk and moderaterisk middle-aged adults and younger elders. 3, 7 The Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III [ATP III]) was the US guideline for who should take statins for the primary prevention of CHD, at what intensities, and to what low-density lipoprotein cholesterol (LDL-C) goals from its release in 2002 until 2013. 8 In 2013, an American College of Cardiology/American Heart Association (ACC/AHA) panel revisited this guideline and recommended that all individuals with clinical atherosclerotic cardiovascular disease (ASCVD), all individuals 40 to 75 years of age with diabetes mellitus and LDL-C ≥70 to 190 mg/dL, and all individuals >20 years of age with LDL-C >190 mg/dL should either start or continue statin use for the prevention of CHD and stroke. 9 The panel also recommended statins for the primary prevention for a fourth, lower-risk group: those 40 to 75 years of age with 10-year ASCVD risk of ≥7.5%. However, the ACC/AHA panel recommended that the last group consider statins only after a clinician-patient risk discussion that included review of the potential for ASCVD reduction, other risk factors, lifestyle, adverse effects, drug-drug interactions, and patient preferences. Assuming that these discussions end with the patient starting a statin, the ACC/ AHA guideline would nearly double the population of individuals in the United States taking statins, with considerable potential impact on ASCVD prevention. 10, 11 The guideline has been controversial for its breadth of statin use, 10 especially given recent evidence that daily medication use causes a nontrivial disutility for many individuals (also called pill burden). 12, 13 Reviewers have also questioned its (largely LDL-C-independent) risk calculation method 14 and its abolition of LDL-C treatment goals. 15 Recent research compared the cost-effectiveness of differing 10-year risk-based thresholds for statin use relative to the ACC/AHA 7.5% cutoff, finding that treatment remains cost-effective at a $100 000 per quality-adjusted life-year (QALY) threshold using risk cutoffs <7.5%. 16, 17 Subsequent work has demonstrated that, for individuals with and without ASCVD and diabetes mellitus, full adherence to the ACC/AHA guideline could prevent >240 000 ASCVD events, chiefly in individuals with high baseline risk. 11 The populationlevel benefit of risk-based and LDL-C-based statin use thresholds in the primary prevention of ASCVD end points such as CHD and stroke has not been compared.
We used the Cardiovascular Disease Policy Model (CVDPM), 18 a Markov model of CHD and stroke in the United States, to evaluate the efficacy and cost-effectiveness of the ACC/AHA guideline for statin use, relative to the ATP III guideline, in men 45 to 74 years of age and women 55 to 74 years of age without CHD, stroke, or diabetes mellitus for the prevention of ASCVD end points (CHD and stroke) and death. We compared these 2 strategies with current levels of statin use (as measured by national surveys) and with universal use of low-dose statins in this age-and sex-based cohort (men 45-74 and women 55-74 years of age).
METHODS

Structure of the Model
The CVDPM is an established computer-simulated statetransition (Markov) cohort model of CVD (CHD and all-cause stroke) incidence, prevalence, mortality, and costs among individuals 35 to 94 years of age in the United States. The model predicts CHD and stroke incidence and mortality, as well as all-cause mortality, among those with and without CVD on the basis of age (in 10-year increments), sex, systolic blood pressure, smoking status, high-density lipoprotein cholesterol level, LDL-C, diabetes mellitus, and statin use. The model does not currently incorporate race or ethnicity as a CHD or stroke risk factor.
The model has 3 components. First, a demographic-epidemiological submodel estimates the incidence of CHD and
Clinical Perspective
What Is New?
• We compared 3 approaches to prescribing statins for primary prevention using simulation modeling and found all 3 (Adult Treatment Panel III, American College of Cardiology/American Heart Association, and broader use of statins regardless of cardiovascular risk) to be effective and cost saving. • This result is highly sensitive to the perceived burden associated with taking a daily medication.
What Are the Clinical Implications?
• Clinicians should offer statins for the primary prevention of cardiovascular disease events and associated mortality both according to the current American College of Cardiology/American Heart Association guideline and potentially for select patients outside this guideline.
• A patient's preference for taking a daily pill is an important factor in assessing whether statin use results in net benefit.
its sequelae (cardiac arrest, myocardial infarction, angina, or CHD-related death), stroke, and death resulting from other causes on the basis of the above risk factors. Second, a bridge submodel characterizes all incident CHD and stroke events and related events over the following 30 days with respect to their impact on subsequent CVD events and deaths. Third, a disease-history submodel predicts the number of subsequent CHD and stroke events, revascularization procedures, and deaths among individuals who have experienced such a CHD or stroke event, stratified by age, sex, and history of CHD or stroke events. Modifiable components of the model include population distributions, risk factor levels and distributions, risk factor (β) coefficients, event rates, case fatality rates, costs, and disability adjustments. 18 Risk factor levels, distributions, and β coefficients are derived from NHANES (National Health and Nutrition Examination Survey) and the Framingham Cohort Study among other sources and reflect both an intrinsic increase in CVD events after diagnosis and the lifestyle factors that precipitated CVD. 19, 20 The predictive value of the model for cardiac end points such as nonfatal myocardial infarction or death resulting from CHD has been validated against empirical data such as WOSCOPS (West of Scotland Coronary Prevention Study). 21 Each health state and event has an annual cost and quality-of-life adjustment. More details are published elsewhere.
18,22,23
Data Sources
The CVDPM uses population size projections for 2010 through 2050 from the US Census 24 and data from NHANES, 2007 to 2010, to estimate the prevalence and mean of CVD risk factors and the joint distribution of risk factors. 19 The background prevalence of CVD is estimated from the National Health Interview Survey, 2009 through 2011, 25 and CVD deaths, prehospital deaths resulting from cardiac arrest, and non-CVD deaths from US Vital Statistics 26 on the basis of codes from the International Classification of Diseases, 10th Revision. 27 Case-fatality rates are derived from the National Hospital Discharge Survey (2010). 28 The β coefficient for the effect of LDL-C lowering on CHD was derived from the CTT (Cholesterol Treatment Trialists) 2012 meta-analysis from 27 randomized trials. 3 The CTT report an independent relative risk reduction of 0.79 for any major coronary event per 1-mmol/L reduction in LDL-C from statins regardless of baseline LDL-C, 3 and we modeled statin efficacy via this relationship. The β coefficients for the effect of LDL-C lowering on stroke were derived from Framingham Heart Study data. 20 We derived the β coefficient for the effect of statins on incident diabetes mellitus from a meta-analysis 29 reporting 1 new case of diabetes mellitus for every 1020 person-years of statin use.
Our statin analysis estimated total healthcare costs through national data from the Centers for Medicare & Medicaid Services. 30 We estimated the CHD cost component using California data, 31 deflated using cost-to-charge ratios, 32 and the ratio of the US national average costs to the California average 33 and then inflated to 2016 dollars using the Bureau of Labor Statistics Consumer Price Index. 34 We based quality-oflife weights on observational data from the Global Burden of Disease study 35 and discounted costs and QALYs at 3%/y. We derived the prevalence of statin use from NHANES survey data.
19
Statin Therapy
We characterized statin doses that decrease LDL-C level by ≈40% (eg, pravastatin 40 mg) as moderate intensity and 55% reduction (eg, atorvastatin 80 mg) as high intensity. 9, 36, 37 We estimated medication cost for base-case scenarios at $48/y for moderate-intensity statins (Table 1) , as found at Wal-Mart, Target, and other national pharmacy chains, 38, 39 and $148.30/y for high-intensity statins, as found at Costco, 46 and we assumed stable prices over the 10 years of statin use modeled.
We derived side-effect rates for incident myopathy, hemorrhagic (not ischemic) stroke, and diabetes mellitus resulting from statins from systematic reviews of statin trials. 9, 29, 50 We based assumptions about patient monitoring requirements and about the consequences of myopathy, hemorrhagic stroke, and diabetes mellitus on both clinical judgment and consensus disutility weights (Table 1) . 35, 47, 48 We presumed an additional penalty of 0.0001 QALYs per person-year to account for additional unforeseen toxicities (Table 1) . We derived the costs of hospitalization for hemorrhagic stroke, laboratory testing, diabetes mellitus, and physician fees from the Center for Medicare & Medicaid Services, the Medical Expenditure Panel Survey, and hospital discharge data, among other sources. 30, [43] [44] [45] Given debate about whether randomized controlled trials underreport the toxicity associated with long-term statin use, we performed Monte Carlo probabilistic sensitivity analyses, increasing the penalty from unforeseen toxicities to as high as 0.001 per year. Given the evidence of a decrement in quality of life associated with daily pill use, 12 we concurrently performed probabilistic sensitivity analyses with a pill burden decrement of up to 0.00384 QALYs lost per year, the equivalent of losing 2 weeks of perfect health over 1 decade, a value derived from patient interviews.
12, 49 We did not assign a QALY penalty for statin use in base analyses. We assumed 100% uptake of therapy, with adherence rates comparable to those observed in intention-to-treat trials.
3
Comparing Lipid-Lowering Strategies
We modeled 4 scenarios for primary prevention. In each scenario, we assumed universal use of high-intensity statins among those with CVD or diabetes mellitus. For individuals without CVD or diabetes mellitus, we modeled the following: ; however, the ACC/ AHA guideline, like the ATP III guideline, recommends annual LDL-C testing to gauge adherence and response to therapy, despite its shift to a risk-based statin prescribing threshold. 9 Therefore, we presumed only 1 liver panel over 10 years in all scenarios and presumed annual LDL-C monitoring in both the ATP III and ACC/AHA scenarios (but not the universal age/ sex-based scenario).
In the ATP III analyses, we modeled high-dose statin treatment in all individuals with a 10-year Framingham CHD (not CVD) risk of ≥20%. If such individuals had risk ≥20% despite a statin, we assumed prior moderate-dose statin use and modeled switching to high-dose by modeling the incremental benefit and cost of switching from moderate-to high-dose statin. We modeled treating all individuals with a calculated 10-year risk <20% and no CHD or diabetes mellitus with a moderate-dose statin to decrease LDL-C below target (130 or 160 mg/dL).
In the ACC/AHA analyses, we modeled treating all individuals with LDL-C of ≥190 mg/dL and not currently taking a statin with a high-dose statin (55% decrease in LDL-C) regardless of other risk factors. 9 For individuals with LDL-C <190 mg/dL, we modeled treatment with a moderate-dose statin among those with a 10-year CVD risk of ≥7.5%, calculated with the ACC/AHA Pooled Cohort Risk Equation. 9, 52 In the universal age/sex-based analysis, we modeled moderate-intensity or high-intensity statin use according to ACC/AHA criteria as above and moderate-intensity for all other 45-to 74-year-old men and 55-to 74-year-old women regardless of LDL-C level, lifestyle risk factors, or other exclusion criteria.
All interventions were modeled on a 10-year horizon in men 45 to 74 years of age and women 55 to 74 years of age. Women <55 years of age were excluded because of the possible teratogenicity of statins 53 and their relatively low risk of CVD. Men 35 to 45 years of age were excluded because of the ACC/AHA's application of its 10-year risk guideline only to individuals ≥40 years of age. 9 Individuals ≥75 years of age were excluded because of limited data on primary prevention in this group and the suggestion that their statin treatment guidelines should be individualized.
9,22,54
Statistical Analyses
For each intervention, we calculated the difference in total individuals started on statins, costs, incident CVD events, deaths, and QALYs between the baseline scenario of status quo statin treatment and the intervention scenario (eg, complete adherence to ACC/AHA guidelines) over 10 years. We calculated the incremental cost-effectiveness ratio as the quotient of the difference in total costs (numerator) over the difference in total QALYs (denominator). We also calculated the incremental cost-effectiveness ratio relative to the next most extensive intervention. Lastly, we calculated the number needed to treat (NNT) for each scenario as the number of individuals needing to undergo 10 years of treatment to save 1 QALY.
We performed deterministic analyses with single-variable changes, as well as probabilistic sensitivity analyses, in which multiple key inputs were repeatedly varied. To isolate the impact of unforeseen statin toxicities, we repeated the analysis with an additional penalty equivalent to 0.001 QALY lost per person-year of statin use. To isolate the impact of differing treatment thresholds on the efficacy of the ACC/AHA strategy relative to ATP III, we repeated ACC/AHA analyses with the 10-year ACC/AHA ASCVD risk threshold for treatment adjusted from 7.5% to 5%, 10% (the threshold also used by the European Society for Cardiology's separate calculator for first fatal ASCVD event), 16 15%, and 20%.
We performed Monte Carlo probabilistic sensitivity analyses in which we varied the cost of statins, incidence and severity of statin toxicities, disutility associated with daily pill use, statin-related medical costs, and impact of statins on LDL-C (Table 1) . We also varied the modeled relationship (β coefficient) for the effect of LDL-C reduction on CHD incidence and the effect of statins on incident diabetes mellitus. These variations assumed a normal or logarithmic distribution derived from empirical data. For example, we varied the cost of moderate-and high-dose statins from $10.57 and $31.71 to $438 and $1217 per person-year, respectively, on the basis of data from Veterans Affairs wholesale prices and Consumer Reports nongeneric drug price data. [40] [41] [42] In the Monte Carlo simulations, we generated 95% uncertainty intervals around our primary outcome measures for each intervention scenario. The 95% confidence intervals corresponding to the effect of each of these variations on statin cost, toxicity, and other inputs are displayed in Table 1 . For example, over 1000 simulations, the total cost of annual statin use varied from $30.11 to $286.90, and the harms associated with statin use, from both medication toxicity and pill burden, varied from roughly 0.00003 to 0.005 QALYs per annum (Table 1) . There were 1000 random draws from a standard normal distribution, scaled to the mean and confidence interval, for each varied parameter. The Monte Carlo program, written in Python, generates a new set of input parameters drawn from the distributions for each iteration, runs the given iteration baseline and intervention simulations with the new parameters, and stores the outcomes for each. The 95% uncertainty intervals for each outcome were then calculated with Microsoft Excel 2010. The work was approved by the Institutional Review Board of the University of California, San Francisco. Because all data were deidentified, informed consent was not required.
RESULTS
In the baseline status quo scenario, we estimate that 13.9 million men 45 to 75 years of age and women 55 to 75 years of age without CVD or diabetes mellitus would be on statins in 2016 (22% of all in these groups). Full implementation of the ATP III guideline in this group would require de novo or intensified statin use among 8.8 million people (7.6 Have LDL-C >190 mg/dL regardless of other risk factors
Have LDL-C >160 mg/dL, ≥2 CHD risk factors, 7 and a Framingham 10-year CHD risk <10%
Have LDL-C <190 mg/dL but have an ACC/AHA 10-year CHD risk >7.5% 8 Have LDL-C 190 mg/dL and <2 CHD risk factors ACC/AHA indicates American College of Cardiology/American Heart Association; ATP III, Adult Treatment Panel III; CAD, coronary artery disease; CHD, coronary heart disease; and LDL-C, low-density lipoprotein cholesterol. million started on statins de novo, 1.2 million with prior dose intensified), increasing the total treated by 23% to 22.7 million (Table 3) . Alternatively, full implementation of the ACC/AHA criteria, assuming all clinician-patient risk discussions result in statin treatment, would raise the prevalence of statin use in this population to 55%, treating 12.3 million more than the maximum under ATP III (Table 3) . Treatment of all men 45 to 74 years of age and women 55 to 74 years of age would add 49.9 million statin users compared with the status quo or 28.9 million relative to the ACC/AHA guideline. Neither the ACC/AHA nor the age/sex-based strategy intensified statin therapy among any individuals already receiving statins in the base case.
The treatment costs associated with each scenario rise roughly in proportion to the number of individuals treated. The total costs associated with each scenario, which incorporate costs from medication prices and toxicity and savings from CVD events averted and lower costs associated with chronic CVD, were negative in each of the 3 scenarios (including universal use in the age/sex cohort) relative to the status quo, indicating that each scenario was cost-saving for CVD compared with current treatment. Full adherence to ACC/AHA resulted in the greatest treatment cost of the 3 scenarios: $6.36 billion in screening costs (eg, liver and lipid panel testing), including approximately $4.40 billion attributable to the cost of annual lipid panel testing not included in the age/sex universal scenario (Tables 1 and  3 ) and the remainder from physician visits, liver panels, and adverse outcomes.
The number of QALYs and lives saved rose as the number of individuals on statins increased. However, increasingly broad criteria for statin use targeted everlarger proportions of individuals with low CVD risk, such that the efficiency of additional statin use declined in terms of the NNT per additional QALY gained (Figure 1) . The ACC/AHA guideline treats 2.4-fold more individuals than ATP III but would save 1.7-fold additional QALYs (Table 3 ). An age/sex-based guideline would increase the number of people treated by 2.4-fold compared with ACC/AHA but would increase QALYs by a factor of 1.6 (Table 3 ). In both women and men, all strategies were cost-saving relative to the next broadest strategy, but the NNT increases as the guideline broadened (35 for ATP III, 68 for ACC/AHA, and 108 for age/ sex-based treatment).
The impact of a broadening statin guideline differed between women and men ( Table 4 ). All statin strategies were cost-saving for men relative to the next broadest strategy, such that ACC/AHA dominated ATP III and the age/sex-based strategy dominated ACC/ AHA in turn. However, in women, the ACC/AHA strategy was not cost-saving relative to the ATP III strategy: Its marginal cost per QALY was $3400. The benefit of each strategy relative to the status quo and relative to the next broadest strategy was substantially greater in men, overall, and across all age subgroups (Table 4 and Tables I and II in the online-only Data Supplement). The marginal NNT to save 1 QALY under the ACC/AHA strategy (relative to the ATP III strategy), for example, was 36 in men 65 to 74 years of age but 69 in women 65 to 74 years of age. For the age/sex-based scenario, relative to ACC/AHA, the marginal NNT in men 55 to 64 years of age was 73, but for women in the same age decile, it rose to 156 (Table II in the online-only Data Supplement). In all cases, older individuals and men derived greater net benefit than younger individuals and women.
Sensitivity Analyses
Results were sensitive to variations in the costs of statins, the extent of toxicity, and the disutility of taking a pill daily. However, results were robust to the change in treatment threshold under the ACC/AHA guideline on the basis of 10-year cardiovascular risk, from 7.5% by default (Table 2 ) to other thresholds between 5% and 20% (Figure 1 ). Shifting the risk threshold for treatment under ACC/AHA from 7.5% to 5% would treat 8.6 million more people and save 21 600 more lives; this shift would change NNT per life saved, relative to the status quo, from 49 to 55 (Figure 1) . Conversely, raising the ACC/AHA treatment threshold to 10% would treat 3.9 million fewer people and save 10 400 fewer lives but lower the NNT to 45 from 49. At a threshold of 15%, the number treated under ACC/ AHA drops by 10.5 million, but the NNT drops to 40, a result nearly on par with ATP III ( Figure 1) ; at 20%, ACC/AHA treats 1.1 million fewer people than ATP III but at a lower NNT of 34. Adding an overall QALY penalty of 0.001 per year to each scenario increased the marginal NNT for the 3 strategies from 35, 68, and 108 to 45, 217, and 559 for ATP III, ACC/AHA, and age/sex strategies, respectively.
Probabilistic analyses demonstrated consistent results across a variety of cost and toxicity thresholds (Figure 2) . To isolate the impact of pill burden on our results, we repeated these probabilistic analyses presuming zero pill burden (but preserving statin harms associated with medication toxicity). Figure 2 displays the impact of each of the 1000 simulations for each scenario on net QALYs saved (x axis) and net cost (y axis) relative to the status quo. Without pill burden (top row), all of the simulations were cost-saving under ATP III, all but 1 under ACC/AHA, and all but 1 in the age/ sex scenario; no simulations resulted in a negative NNT (indicating net harm) in any of the 3 scenarios. When pill burden was included in the simulations (bottom row), all of the simulations were cost-saving under ATP III, but a small number of simulations were no longer cost-saving under ACC/AHA and the age/sex-based scenario. Similarly, although none of the ATP III simulations resulted in net harm, 5 simulations in the ACC/ AHA scenario and 34 in the age/sex-based scenario did result in net harm.
DISCUSSION
We project that full adherence to the ACC/AHA guideline in the United States among individuals without CVD or diabetes mellitus, compared with their full adherence to ATP III, would avert thousands more CVD events and deaths over 10 years while producing net cost savings for CVD in men and a cost-effective outcome ($3400 per marginal QALY saved) in women. Full adherence to ATP III, ACC/AHA, and age/sex-based criteria is beneficial and cost-saving compared with current rates of statin use for men and women combined. At a population level, this result is robust to large alterations of the 10-year risk threshold for treatment from 20% to 0% (treatment of all individuals in this agesex cohort). However, benefit is moderately sensitive to the estimated toxicity of statins and highly sensitive to the variation in disutility associated with statin use. In other words, an individual patient's degree of benefit from long-term statin use depends strongly on personal tolerance for pill burden and some on projected side effects, both of which are more important than the patient's degree of cardiovascular risk.
We found that risk-based statin guidelines (such as ACC/AHA) and LDL-C-based strategies (such as ATP III) have nearly identical NNTs per QALY saved when ACC/AHA indicates American College of Cardiology/American Heart Association; ATP III, Adult Treatment Panel III; CHD, coronary heart disease; ICER, incremental cost-effectiveness ratio; NNT, number needed to treat; and QALY, quality-adjusted life-year. *A total of 7.6 million started on statins de novo, 1.2 million with prior dose intensified.
directed at comparably sized populations of relatively equal baseline cardiovascular risk. However, because the incidence of statin toxicity is independent of cardiovascular risk, treatment of broader, lower-risk populations (eg, by lowering the ACC/AHA treatment threshold) may create scenarios in which the collective toxicity burden outweighs cardiovascular benefit. For example, when the ACC/AHA risk-based approach is applied at a 20% threshold, it has an NNT similar to ATP III relative to the status quo (34 versus 35) and treats a similar number of people (Figure 1) . However, at its default threshold of 7.5% (per ACC/AHA guidelines), the ACC/AHA's threshold relative to the status quo rises to 49, and its marginal NNT increases to 68, as it treats 12.3 million more people. At a 5% treatment threshold, the NNT of the ACC/AHA strategy rises to 55 relative to the status quo, with a marginal NNT of 72, as it treats 21.3 million individuals more than ATP III. Similarly, inclusion of individuals with CVD and diabetes mellitus would likely lower the NNT even further than applying a 20% risk threshold in this CVD/ diabetes mellitus-free cohort. Egan et al 11 recently reported a 10-year NNT of 18 for a similar ACC/AHA scenario including individuals with ASCVD and diabetes mellitus, although this approach also presumed both more frequent use of high-intensity statins and a greater reduction in ASCVD risk per 1-mmol/L drop in LDL-C from statin treatment.
Accounting for the known potential harms associated with statin use, plus adding an additional penalty to account for toxicities or harms yet to be identified, decreases their benefit, especially for the ACC/AHA and age/sex-based scenarios. However, all 3 strategies remain both beneficial (although with a high NNT) and cost-saving overall relative to the status quo. Assuming no pill burden but varying incidence and severity of all known toxicities associated with statin use by 50% to ≥150% and the cost of statins by a factor of >20 also had minimal effect on all 3 strategies, with almost all of the 1000 Monte Carlo simulations for each strategy remaining efficacious and cost-saving ( Figure 2, top row) . This result suggests that even substantial variation in the estimated toxicity and price of statins produces little absolute difference in their overall toxicity and cost-effectiveness because the absolute risk associated with these toxicities is low and the cost-effectiveness of statins is substantive even at high-end prices. However, accounting for even modest estimates of the potential pill burden associated with statins substantially diminishes the efficacy of statins (Figure 2 , bottom row). A pill disutility equivalent to 2 weeks of lost perfect health over a decade, a level identified by patient preference interviews, 12, 49 corresponds to an annual QALY penalty more than triple the high-end toxicity estimate in the probabilistic analyses above. When this penalty is added to these probabilistic analyses, full adherence to the ACC/AHA and age/sex-based strategies may result in net harm in the population relative to the status quo (Figure 2 , bottom row, quadrants III and IV).
Although our results confirm that broad statin use for all individuals, even those at low risk, can be costsaving for CVD and result in net benefit, even a modest pill disutility may negate the benefit of statins in these individuals. Current estimates of pill disutility vary widely both between and within empirical studies, 12, 49 likely reflecting real differences in medication disutility among specific targeted individuals. 12 Given that the ACC/AHA guideline recommends a clinicianpatient risk discussion before statin assignment, our results suggest that physicians should also assess each patient's individual preference for daily pill use in making this patient-specific decision, particularly for those at lower risk.
Our study has several limitations. First, because the CVDPM is based in part on observational data, key assumptions (such as the impact of nonfatal cardiac events on later mortality) may be overestimates or underestimates as a result of endogeneity or other factors. For example, the relationship between nonfatal cardiac events and later death may be confounded by lifestyle factors more prevalent in those who experience these events (eg, dietary patterns), such that the measured relationship is an overestimate. Second, on the basis of the ACC/AHA guidelines and substantial prior data, 3 we modeled a constant percent LDL-C reduction for a given intensity of statin and an ageindependent effect of LDL-C-lowering on CVD events and mortality. Although randomized trials suggest a relatively constant level of benefit from statins, 3,9 the existence of this benefit has not been directly proven in all low-risk groups, 14, 55 and the size of this benefit, when present, is uncertain 3 and may vary across the cohorts we studied. For example, because the ACC/ AHA guideline treats a greater number of older individuals than ATP III at all thresholds, our finding of equivalent efficacy at comparable thresholds may not apply if the benefit of statins attenuates with age within the study population (men, 45-74 years; women, 55-74 years), as estimated by observational studies such as the Framingham Heart Study. 20, 56 In addition, we assigned cohorts to treatment under the ACC/AHA risk threshold on the basis of their status at the start of the 10-year simulation, but we did not change this status over that time; as a result, we may have underestimated treatment eligibility under the ACC/AHA guideline. Third, our model incorporates CHD and stroke as elements of CVD but not peripheral artery disease, a third component of ASCVD as defined by the ACC/AHA guideline. Fourth, we assumed that all doctor-patient discussions of statin eligibility under ACC/AHA guidelines led to a decision to start a statin and further assumed 100% adherence, thereby likely overestimating the number of individuals on statins in this scenario. Lastly, the CVDPM has several intrinsic limitations. It does not incorporate race expressly as a risk factor for ASCVD, nor does it incorporate certain nontraditional ASCVD risk factors such as end-stage renal disease. In addition, it does not differentiate between ischemic stroke (against ACC/AHA indicates American College of Cardiology/American Heart Association; ATP III, Adult Treatment Panel III; CHD, coronary heart disease; ICER, incremental cost-effectiveness ratio; NNT, number needed to treat; and QALY, quality-adjusted life-year. which statins are protective) and hemorrhagic stroke (for which statins increase risk), nor is it applicable in individuals <35 years of age. However, we incorporated race as a factor in the identification of populations eligible for statins via ACC/AHA's 7.5% 10-year ASCVD risk threshold, 9, 52 so that the ACC/AHA simulation reflects the impact of tailored therapy by race. We also added hemorrhagic stroke risk as a statin toxicity, partially offsetting the protective effect of statins against all-cause (chiefly ischemic) stroke. 9, 20 We did not model toxicities attributed to statin use for which evidence is sparse or inconsistent such as development of cataracts. 57, 58 However, in a scenario analysis, we included an additional QALY penalty of 0.001 (equivalent to the maximal disutility associated with all known statin toxicities; Table 1 ). In a separate analysis, we also included a QALY penalty of up to 0.00384 for pill disutility. The insight that emerges from these analyses is that at an individual level, the driver of benefit is not the magnitude of the known and unknown medication toxicities of statins but patient preference for taking a pill. A modest pill burden effect would have a greater effect on net QALYs compared with all known statin toxicities.
We project that full adherence to the ACC/AHA statin guideline for men 45 to 74 years of age and women 55 to 74 years of age would save thousands more lives over the decade than full adherence to ATP III or the status quo, with net cost savings at the population level. We also project that the ACC/AHA riskbased guideline is substantively less efficient than ATP III's LDL-C-based approach at its current risk threshold, but the 2 approaches have similar efficiency when treating comparably high-risk pools. Statins remain cost-saving and efficacious in all 3 scenarios even after significant increases in medication toxicity, but a modest pill burden attributable to statins causes their harms to outweigh their benefit in some the ACC/ AHA and age/sex-based scenarios, highlighting the sensitivity of our findings to individual patient preferences. More studies are therefore necessary not only to understand the direct harms from statins but also to gauge the true size of this pill burden and its degree of variation across individuals. Our analyses suggest that in populations at low risk of harms from statin use and unburdened by chronic pill use, broader use of statins would both avert substantive cardiovascular morbidity and prove cost-saving, even when baseline cardiovascular risk is low.
